Antitumor efficacy, tumor distribution and blood pharmacokinetics of chitosan/glyceryl-monooleate nanostructures containing paclitaxel

Nanomedicine

Volumn 6, Issue 3, 2011, Pages 437-448

  Trickler, William J ^a,b   Munt, Daniel J ^a   Jain, Neha ^a   Joshi, Shantaram S ^c   Dash, Alekha K ^a  

^a CREIGHTON UNIVERSITY   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

blood pharmacokinetic parameters; chitosan glyceryl monooleate nanostructures; hematological alterations; histopathological studies; paclitaxel; tumor distribution

Indexed keywords

CHITOSAN; GLYCEROL OLEATE; NANOMATERIAL; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHITOSAN; DRUG DELIVERY SYSTEMS; FEMALE; GLYCERIDES; LEUKOCYTE COUNT; MICE; MICE, INBRED BALB C; NANOSTRUCTURES; NEOPLASMS; PACLITAXEL;

EID: 79955596913     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.135     Document Type: Article

References (41)

1. Moore A, Medarova Z, Potthastand A, Dai G: In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res. 64, 1821-1827 (2004). (Pubitemid 38428707)
2. Sandri G, Bonferoni MC, Rossi S et al.: Nanoparticles based on N-trimethylchitosan: Evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models. Eur. J. Pharm. Biopharm. 65, 68-77 (2007). (Pubitemid 44827693)
3. Bernkop-Schnurch A, Weithaler A, Albrecht K, Greimel A: Thiomers: Preparation and in vitro evaluation of a mucoadhesive nanoparticulate drug delivery system. Int. J. Pharm. 317, 76-81 (2006). (Pubitemid 43866341)
4. Cui F, Qianand F, Yin C: Preparation and characterization of mucoadhesive polymer-coated nanoparticles. Int. J. Pharm. 316, 154-161 (2006). (Pubitemid 43765702)
5. Howard KA, Rahbek UL, Liu X et al.: RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 14, 476-484 (2006). (Pubitemid 44296092)
6. Zheng F, Shi XW, Yang GF et al.: Chitosan nanoparticle as gene therapy vector via gastrointestinal mucosa administration: Results of an in vitro and in vivo study. Life Sci. 80, 388-396 (2007). (Pubitemid 44958716)
7. Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y: Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm. Res. 13, 896-901 (1996). (Pubitemid 26227747)
8. Takeuchi H, Thongborisute J, Matsui Y, Sugihara H, Yamamoto H, Kawashima Y: Novel mucoadhesion tests for polymers and polymer-coated particles to design optimal mucoadhesive drug delivery systems. Adv. Drug Deliv. Rev. 57, 1583-1594 (2005). (Pubitemid 41443471)
9. Thongborisute J, Tsuruta A, Kawabata Y, Takeuchi H: The effect of particle structure of chitosan-coated liposomes and type of chitosan on oral delivery of calcitonin. J. Drug Target. 14, 147-154 (2006). (Pubitemid 43878823)
10. Singla AK, Garg A, Aggarwal D: Paclitaxel and its formulations. Int. J. Pharm. 235, 179-192 (2002). (Pubitemid 34185449)
11. Tarr BD, Yalkowsky SH: A new parenteral vehicle for the administration of some poorly soluble anti-cancer drugs. J. Parenter. Sci. Technol. 41, 31-33 (1987). (Pubitemid 17034075)
12. Chao TC, Chu Z, Tseng LM et al.: Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: A Phase II trial. Invest. New Drugs. 23, 171-177 (2005). (Pubitemid 40386235)
13. Gelderblom H, Verweij J, Nooter K, Sparreboom A, Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37, 1590-1598 (2001). (Pubitemid 32778603)
14. Friedl D, Gorman G, Treat J: Hypersensitivity reactions from taxol and etoposide. J. Natl Cancer Inst. 85, 2036 (1993). (Pubitemid 24000989)
15. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC: Neurotoxicity of Taxol. J. Natl Cancer Inst. Monogr. 15, 107-115 (1993).
16. Jauhari S, Dash AK: A mucoadhesive in situ gel delivery system for paclitaxel. AAPS PharmSciTech. 7, E53 (2006). n Evaluates the formulation of a mucoadhesive paclitaxel in situ gel system containing GMO and chitosan.
17. Trickler WJ, Nagvekar AA, Dash AK: A novel nanoparticle formulation for sustained paclitaxel delivery. AAPS PharmSciTech. 9, 486-493 (2008). nn Describes the preparation and characterization of paclitaxel nanoparticles with GMO and chitosan.
18. Trickler WJ, Khurana J, Nagvekar AA, Dash AK: Chitosan and glyceryl monooleate nanostructures containing gemcitabine: Potential delivery system for pancreatic cancer treatment. AAPS PharmSciTech. 11, 392-401 (2010). nn Describes the usefulness of this GMO and chitosan system for the delivery of hydrophilic drug gemcitabine.
19. Trickler WJ, Nagvekar AA, Dash AK: The in vitro sub-cellular localization and in vivo efficacy of novel chitosan/GMO nanostructures containing paclitaxel. Pharm. Res. 26, 1963-1973 (2009). nn Deciphers the subcellular localization and in vivo efficacy of this novel paclitaxel drug delivery system in two different animal models.
20. O'Neil P, Vital E, Betancourt-Loria N, Montes D: Performance evaluation of the complete blood count and white blood cell differential parameters on the AcT 5diff hematology analyzer. Lab. Hematol. 7, 116-124 (2001). (Pubitemid 32952302)
21. Clark G: Staining Procedures (3rd Edition). Williams & Wilkins, MD, USA, 122 (1972).
22. McKenzie SB: Textbook of Hematology (2nd Edition). Williams & Wilkins, MD, USA, 85-148 (1996).
23. Lillie RD: Histopathologic Technic and Practical Histochemistry. McGraw-Hill, NY, USA, 149-150 (1965).
24. Safavy A: Recent developments in taxane drug delivery. Curr. Drug Deliv. 5, 42-54 (2008). (Pubitemid 351225633)
25. Mugabe C, Hadaschik BA, Kainthan RK, Brooks DE, So AI, Gleave ME: Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. Br. J. Urol. Int. 103, 978-986 (2009).
26. Zhang Z, Lee SH, Gan CW, Feng SS: In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharm. Res. 25, 1925-1935 (2008). n Describes the formulation of polylactide-TPGS nanoparticles, which exhibited significant advantages in an in vivo pharmacokinetics and xenograft tumor model versus PLGA nanoparticle formulation.
27. Nornoo AO, Chow DS: Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. Int. J. Pharm. 349, 117-123 (2008). (Pubitemid 350299696)
28. Dong Y, Feng SS: In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy. Biomaterials 28, 4154-4160 (2007). (Pubitemid 47053934)
29. Lee SW, Chang DH, Shim MS, Kim BO, Kim SO, Seo MH: Ionically fixed polymeric nanoparticles as a novel drug carrier. Pharm. Res. 24, 1508-1516 (2007).
30. Koziara JM, Whisman TR, Tseng MT, Mumper RJ: In vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J. Control. Release 112, 312-319 (2006). (Pubitemid 43737150)
31. Win KY, Feng SS: In vitro and in vivo studies on vitamin E TPGS-emulsified poly(d,l-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials 27, 2285-2291 (2006). (Pubitemid 41774539)
32. Chen DB, Yang TZ, Lu WL, Zhang Q: In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem. Pharm. Bull. 49, 1444-1447 (2001). (Pubitemid 33043274)
33. Sharma D, Chelvi TP, Kaur J, Chakravorty K, De TK, Maitra A: Novel Taxol formulation: Polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy. Oncol. Res. 8, 281-286 (1996). (Pubitemid 26404134)
34. Wang Y, Li Y, Zhang L, Fang X: Pharmacokinetics and biodistribution of paclitaxel-loaded Pluronic P105 polymeric micelles. Arch. Pharm. Res. 31, 530-538 (2008).
35. Han LM, Guo J, Zhang LJ, Wang QS, Fang XL: Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123. Acta Pharmacol. Sin. 27, 747-753 (2006). (Pubitemid 43943925)
36. Kim SC, Kim DW, Shim YH et al.: In vivo evaluation of polymeric micellar paclitaxel formulation: Toxicity and efficacy. J. Control. Release 72, 191-202 (2001). (Pubitemid 32522357)
37. Hamaguchi T, Matsumura Y, Suzuki M et al.: NK105, a paclitaxel- incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br. J. Cancer 92, 1240-1246 (2005). (Pubitemid 40604398)
38. Zhao Z, He M, Yin L et al.: Biodegradable nanoparticles based on linoleic acid and poly(b-malic acid) double graftedchitosan derivatives as carriers ofanticancer drugs. Biomacromolecules 10, 565-572 (2009).
39. van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM: Biodistribution and pharmacokinetic analysis of paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model. Mol. Pharm. 5, 516-526 (2008).
40. Jennens R, Rischin D, Yuen K, Toner G, Millward M: Comparison of neutropenia in a randomized, crossover trial of 3-, 6-, and 24-h infusions of paclitaxel. Gynecol. Oncol. 91, 190-193 (2003). (Pubitemid 37188610)
41. Gianni L, Munzone E, Capri G et al.: Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J. Natl Cancer Inst. 87, 1169-1175 (1995).